Business
Rule 2.9 Announcement
Rule 2.9 Announcement.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 6532Z hVIVO plc 17 January 2020 \n\nhVIVO plc\n \n(\"hVIVO or the \"Company\")\n \nRule 2.9 Announcement\n \nIn accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,664,276 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury. Accordingly, the total number of voting rights in hVIVO is 83,664,276. The International Securities Identification Number (\"ISIN\") for hVIVO's ordinary shares is GB00B6ZM0X53.\n \n \nFor further information please contact:\n \nhVIVO plc +44 (0)20 7756 1300\nAnesh Patel, Interim Finance Director and Company Secretary\nFleur Wood, EVP, Investor Relations & Communications\n \nNumis Securities Limited (Nominated Adviser) +44 (0)20 7260 1000\nFreddie Barnfield / Huw Jeremy\n \nFTI Consulting (Financial PR) +44 (0)20 3727 100\nSimon Conway / Victoria Foster Mitchell\n \n \nNotes to Editors: \nhVIVO plc is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.\n \n\nThis information is provided by R...